Sebastian Zschaeck1,2,3,4, Frank Hofheinz5, Klaus Zöphel6,7,8,9,10, Rebecca Bütof11,8, Christina Jentsch11,8,10, Julia Schmollack11,8, Steffen Löck11,6,7,8,10,12, Jörg Kotzerke6,7,8,9,10, Gustavo Baretton6,7,10,13, Jürgen Weitz6,7,10,14, Michael Baumann11,6,7,8,10,15, Mechthild Krause11,6,7,8,10,15. 1. Department of Radiation Oncology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany. sebastian.zschaeck@uniklinikum-dresden.de. 2. German Cancer Consortium (DKTK), Dresden, Germany. sebastian.zschaeck@uniklinikum-dresden.de. 3. German Cancer Research Center (DKFZ), Heidelberg, Germany. sebastian.zschaeck@uniklinikum-dresden.de. 4. OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Fetscherstr. 74, 01307, Dresden, Germany. sebastian.zschaeck@uniklinikum-dresden.de. 5. PET Center, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. 6. German Cancer Consortium (DKTK), Dresden, Germany. 7. German Cancer Research Center (DKFZ), Heidelberg, Germany. 8. OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Fetscherstr. 74, 01307, Dresden, Germany. 9. Department of Nuclear Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden, Germany. 10. National Center for Tumor Diseases (NCT), Partner site Dresden, Dresden, Germany. 11. Department of Radiation Oncology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany. 12. Biostatistics and Modeling in Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany. 13. Department of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 14. Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 15. Institute of Radiooncology, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany.
Abstract
PURPOSE: Early side effects including oesophagitis are potential prognostic factors in patients undergoing radiochemotherapy (RCT) for locally advanced oesophageal cancer (LAEC). We assessed the prognostic value of 18F-fluorodeoxyglucose (FDG) uptake within irradiated non-tumour-affected oesophagus (NTO) during restaging positron emission tomography (PET) as a surrogate for inflammation/oesophagitis. METHODS: This retrospective evaluation included 64 patients with LAEC who had completed neoadjuvant RCT and had successful oncological resection. All patients underwent FDG PET/CT before and after RCT. In the restaging PET scan maximum and mean standardized uptake values (SUVmax, SUVmean) were determined in the tumour and NTO. Univariate Cox regression with respect to overall survival, local control, distant metastases and treatment failure was performed. Independence of clinically relevant parameters was tested in a multivariate Cox regression analysis. RESULTS: Increased FDG uptake, measured in terms of SUVmean in NTO during restaging was significantly associated with complete pathological remission (p = 0.002) and did not show a high correlation with FDG response of the tumour (rho < 0.3). In the univariate analysis, increased SUVmax and SUVmean in NTO was associated with improved overall survival (p = 0.011, p = 0.004), better local control (p = 0.051, p = 0.044), a lower rate of treatment failure (p < 0.001 for both) and development of distant metastases (p = 0.012, p = 0.001). In the multivariate analysis, SUVmax and SUVmean in NTO remained a significant prognostic factor for treatment failure (p < 0.001, p = 0.004) and distant metastases (p = 0.040, p = 0.011). CONCLUSIONS: FDG uptake in irradiated normal tissues measured on restaging PET has significant prognostic value in patients undergoing neoadjuvant RCT for LAEC. This effect may potentially be of use in treatment personalization.
PURPOSE: Early side effects including oesophagitis are potential prognostic factors in patients undergoing radiochemotherapy (RCT) for locally advanced oesophageal cancer (LAEC). We assessed the prognostic value of 18F-fluorodeoxyglucose (FDG) uptake within irradiated non-tumour-affected oesophagus (NTO) during restaging positron emission tomography (PET) as a surrogate for inflammation/oesophagitis. METHODS: This retrospective evaluation included 64 patients with LAEC who had completed neoadjuvant RCT and had successful oncological resection. All patients underwent FDG PET/CT before and after RCT. In the restaging PET scan maximum and mean standardized uptake values (SUVmax, SUVmean) were determined in the tumour and NTO. Univariate Cox regression with respect to overall survival, local control, distant metastases and treatment failure was performed. Independence of clinically relevant parameters was tested in a multivariate Cox regression analysis. RESULTS: Increased FDG uptake, measured in terms of SUVmean in NTO during restaging was significantly associated with complete pathological remission (p = 0.002) and did not show a high correlation with FDG response of the tumour (rho < 0.3). In the univariate analysis, increased SUVmax and SUVmean in NTO was associated with improved overall survival (p = 0.011, p = 0.004), better local control (p = 0.051, p = 0.044), a lower rate of treatment failure (p < 0.001 for both) and development of distant metastases (p = 0.012, p = 0.001). In the multivariate analysis, SUVmax and SUVmean in NTO remained a significant prognostic factor for treatment failure (p < 0.001, p = 0.004) and distant metastases (p = 0.040, p = 0.011). CONCLUSIONS:FDG uptake in irradiated normal tissues measured on restaging PET has significant prognostic value in patients undergoing neoadjuvant RCT for LAEC. This effect may potentially be of use in treatment personalization.
Entities:
Keywords:
FDG pet; Inflammation; Oesophageal cancer; Radiochemotherapy; Side effects
Authors: Elena Elimova; Xuemei Wang; Elba Etchebehere; Hironori Shiozaki; Yusuke Shimodaira; Roopma Wadhwa; Venkatram Planjery; Nikolaos Charalampakis; Mariela A Blum; Wayne Hofstetter; Jeff H Lee; Brian R Weston; Manoop S Bhutani; Jane E Rogers; Dipen Maru; Heath D Skinner; Homer A Macapinlac; Jaffer A Ajani Journal: Eur J Cancer Date: 2015-08-28 Impact factor: 9.162
Authors: Angel C Rebollo Aguirre; Carlos Ramos-Font; Román Villegas Portero; Gary J R Cook; José M Llamas Elvira; Antonio Romero Tabares Journal: Ann Surg Date: 2009-08 Impact factor: 12.969
Authors: N S Russell; A Grummels; A A Hart; I J Smolders; J Borger; H Bartelink; A C Begg Journal: Int J Radiat Biol Date: 1998-06 Impact factor: 2.694
Authors: Shulian Wang; Jeff Campbell; Matthew H Stenmark; Paul Stanton; Jing Zhao; Martha M Matuszak; Randall K Ten Haken; Feng-Ming Kong Journal: Radiother Oncol Date: 2018-03 Impact factor: 6.280
Authors: Constantin Lapa; Ursula Nestle; Nathalie L Albert; Christian Baues; Ambros Beer; Andreas Buck; Volker Budach; Rebecca Bütof; Stephanie E Combs; Thorsten Derlin; Matthias Eiber; Wolfgang P Fendler; Christian Furth; Cihan Gani; Eleni Gkika; Anca-L Grosu; Christoph Henkenberens; Harun Ilhan; Steffen Löck; Simone Marnitz-Schulze; Matthias Miederer; Michael Mix; Nils H Nicolay; Maximilian Niyazi; Christoph Pöttgen; Claus M Rödel; Imke Schatka; Sarah M Schwarzenboeck; Andrei S Todica; Wolfgang Weber; Simone Wegen; Thomas Wiegel; Constantinos Zamboglou; Daniel Zips; Klaus Zöphel; Sebastian Zschaeck; Daniela Thorwarth; Esther G C Troost Journal: Strahlenther Onkol Date: 2021-07-14 Impact factor: 3.621